| |
18 h
in vitro
treatment
|
---|
| | |
Medium
|
IL-12
|
IL-18
|
IL-12 + IL-18
|
---|
Controls (n = 26)
|
Percentage (%)
|
CD3
−
CD56
+
|
13.76 ± 1.75#
|
14.58 ± 2.67
|
13.92 ± 2.66
|
12.47 ± 2.14
|
CD3
−
CD56
dim+
|
12.72 ± 1.76
|
13.39 ± 2.64
|
12.04 ± 2.26
|
11.53 ± 2.13
|
CD3
−
CD56
bright+
|
1.06 ± 0.11
|
1.18 ± 0.15
|
1.07 ± 0.20
|
0.90 ± 0.12
|
Apsolute values (/μl)
|
CD3
−
CD56
+
|
261.53 ± 19.33
|
280.53 ± 29.33
|
255.28 ± 21.38
|
275.14 ± 23.33
|
CD3
−
CD56
dim+
|
250.87 ± 30.54
|
260.71 ± 32.55
|
249.39 ± 33.83
|
259.12 ± 35.22
|
CD3
−
CD56
bright+
|
19.63 ± 1.39
|
21.13 ± 0.19
|
18.87 ± 0.09
|
20.18 ± 1.01
|
Patients (n = 36)
|
Percentage (%)
|
CD3
−
CD56
+
|
16.61 ± 1.99
|
16.82 ± 2.11
|
17.70 ± 2.42
|
17.72 ± 2.31
|
CD3
−
CD56
dim+
|
15.56 ± 1.96
|
15.82 ± 2.10
|
16.63 ± 2.40
|
16.66 ± 2.29
|
CD3
−
CD56
bright+
|
1.05 ± 0.09
|
1.06 ± 0.08
|
1.07 ± 0.10
|
1.03 ± 0.12
|
Apsolute values (/μl)
|
CD3
−
CD56
+
|
328.32 ± 21.33
|
319.83 ± 28.33
|
319.83 ± 25.13
|
338.51 ± 23.33
|
CD3
−
CD56
dim+
|
305.13 ± 20.96
|
300.75 ± 39.73
|
321.27 ± 27.23
|
325.17 ± 27.71
|
CD3
−
CD56
bright+
|
22.87 ± 0.19
|
25.34 ± 0.09
|
26.13 ± 0.33
|
20.01 ± 0.10
|
- #Results are expressed as mean values ± SE. Absolute numbers were calculated by multiplying PBL number in the blood count with percentage for each subset obtained by flow cytometry.